-transparent.png){kind=logo}
The pyrido derivatives of amsacrine [4'-(9-acridinylamino) methanesulfon-m-anisidine] were prepared and evaluated in the L1210 leukemia system. Almost all the pyrido analogues were tighter DNA-binding ligands than the corresponding amsacrine compounds. The significant inhibition of L1210 produced by pyrido-acridan-7-ones demonstrates that the anilino side chain is not essential for activity, although most of the compounds did not have improved activity compared with amsacrine.
Related Publications
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
November 1978,
Journal of medicinal chemistry,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
November 1975,
Journal of medicinal chemistry,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
May 1993,
Journal of medicinal chemistry,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
September 1999,
Bioorganic & medicinal chemistry,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
July 1996,
Chemical & pharmaceutical bulletin,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
June 1981,
Journal of medicinal chemistry,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
May 2012,
Organic & biomolecular chemistry,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
September 2008,
Journal of medicinal chemistry,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
May 1980,
Journal of medicinal chemistry,
E Llama, and
C Del Campo, and
M Capo, and
M Anadon
September 1986,
Journal of medicinal chemistry,
